Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Ameren Corporation (AEE) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ameren Corporation (AEE) - free report >>
Image: Bigstock
Top Ranked Momentum Stocks to Buy for November 23rd
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 23rd:
Arbutus Biopharma Corporation (ABUS - Free Report) : This owner and operator of a biopharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.7% over the last 60 days.
Arbutus Biopharma Corporation Price and Consensus
Arbutus Biopharma Corporation price-consensus-chart | Arbutus Biopharma Corporation Quote
Arbutus’ shares gained 13.6% over the last one month more than S&P 500’s loss of -0.2%. The company possesses a Momentum Score of A.
Arbutus Biopharma Corporation Price
Arbutus Biopharma Corporation price | Arbutus Biopharma Corporation Quote
Opexa Therapeutics, Inc. (ACER - Free Report) : This owner and operator of a pharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 4.5% over the last 60 days.
Opexa Therapeutics, Inc. Price and Consensus
Opexa Therapeutics, Inc. price-consensus-chart | Opexa Therapeutics, Inc. Quote
ACI’s shares gained 6.5% over the last one month. The company possesses a Momentum Score of A.
Opexa Therapeutics, Inc. Price
Opexa Therapeutics, Inc. price | Opexa Therapeutics, Inc. Quote
Ameren Corporation (AEE - Free Report) : This owner and operator of a public utility holding company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.7% over the last 60 days.
Ameren Corporation Price and Consensus
Ameren Corporation price-consensus-chart | Ameren Corporation Quote
Ameren’s shares gained 1.1% over the last one month. The company possesses a Momentum Score of B.
Ameren Corporation Price
Ameren Corporation price | Ameren Corporation Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>